Sibutramine: current status as an anti-obesity drug and its future perspectives

By Sharma Bikash   Henderson David C  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2161-2173

Informa Healthcare

Access to resources Recommend Favorite

Safety Assessment of an Anti-Obesity Drug (Sibutramine): A Retrospective Cohort Study

By Tyczynski Jerzy E.  

Drug Safety, Vol. 35, Iss. 8, 2012-08 ,pp. : 629-644

Adis International

Access to resources Recommend Favorite

Orlistat: its current status as an anti-obesity drug

By Ballinger A.   Peikin S.R.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 109-117

Elsevier

Access to resources Recommend Favorite

Anti-obesity drug development

By Bays Harold   Dujovne Carlos  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1189-1204

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

By Parker E.   Van Heek M.   Stamford A.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 173-187

Elsevier

Access to resources Recommend Favorite